Evidence map›Paper›PMID 41831571›Full record

ArticleMolecular & cellular proteomics : MCP2026

Glycoinformatic Profiling of Label-Free Intact Heparan Sulfate Oligosaccharides.

Marissa L Maciej-Hulme, Jandi Kim, Elijah T Roberts, Yiqing Zhang, Anouk van der Velden, Dirk den Braanker, Cansu Yanginlar, Mark de Graaf, Ton Rabelink, Bernard van den Berg and 5 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marissa L Maciej-HulmeDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands; Division of Pharmacy, Department of Life Science and Health, Faculty of Health Sciences, OsloMet, Oslo, Norway. Electronic address: marissa.maciej-hulme@oslomet.no.
Jandi KimDepartment of Chemistry, University of Georgia, Athens, Georgia, USA.
Elijah T RobertsDepartment of Chemistry, University of Georgia, Athens, Georgia, USA.
Yiqing ZhangDepartment of Chemistry, University of Georgia, Athens, Georgia, USA.
Anouk van der VeldenDepartment of Internal Medicine (Nephrology), Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory of Vascular and Regenerative Medicine, LUMC, Leiden, The Netherlands.
Dirk den BraankerDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Cansu YanginlarDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Mark de GraafDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Ton RabelinkDepartment of Internal Medicine (Nephrology), Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory of Vascular and Regenerative Medicine, LUMC, Leiden, The Netherlands.
Bernard van den BergDepartment of Internal Medicine (Nephrology), Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory of Vascular and Regenerative Medicine, LUMC, Leiden, The Netherlands.
Ellen van OmmenDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Rutger MaasDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Anne-Els van de LogtDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
I Jonathan AmsterDepartment of Chemistry, University of Georgia, Athens, Georgia, USA.
Johan van der VlagDepartment of Nephrology, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heparan sulfates (HSs) are a group of heterogenous linear, sulfated polysaccharides that play a role in health and many diseases, including cancer, cardiovascular, and kidney diseases. The structural variety of HS has greatly challenged the development and utility of HS analytics, particularly for native (nondepolymerized) structures, leaving a significant gap in HS technologies for clinical application. Mass spectrometry-based profiling with bioinformatics offers an approach that can retain variety in large datasets. Using healthy human plasmas, we developed a mass spectrometry glycoprofiling approach for native HS oligosaccharides, which retains the structural complexity of each individual HS chain and generates an HS "index" (or Heparan-ome) for each patient. As a proof of concept, analysis of 53 plasma samples ranging from four groups of kidney disease patients revealed a new subset cluster (21%, 4/19) of membranous glomerulopathy patients with distinct HS profiles, highlighting the potential of HS glycoprofiling as a powerful new approach to clinical practice, which warrants future development into quantitative oligosaccharide glycosaminoglycanomics and clinical diagnostics of kidney and other diseases.

Indexed as

GlycomicsHeparan SulfateOligosaccharidesHumansMass SpectrometryHeparan SulfateOligosaccharidesglycomicsheparan sulfateheparan sulfate profilingkidney diseasemass spectrometry

Identifiers

PMID41831571
PMCPMC13101687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.